JP2008536487A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008536487A5 JP2008536487A5 JP2008501411A JP2008501411A JP2008536487A5 JP 2008536487 A5 JP2008536487 A5 JP 2008536487A5 JP 2008501411 A JP2008501411 A JP 2008501411A JP 2008501411 A JP2008501411 A JP 2008501411A JP 2008536487 A5 JP2008536487 A5 JP 2008536487A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- activated
- tumor cell
- atcp
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000822 natural killer cell Anatomy 0.000 claims 13
- 238000002360 preparation method Methods 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 210000004881 tumor cell Anatomy 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 230000003827 upregulation Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0505508A GB0505508D0 (en) | 2005-03-17 | 2005-03-17 | Method |
| GB0505508.2 | 2005-03-17 | ||
| GB0514288.0 | 2005-07-12 | ||
| GB0514288A GB0514288D0 (en) | 2005-07-12 | 2005-07-12 | Method |
| PCT/GB2006/000960 WO2006097743A2 (en) | 2005-03-17 | 2006-03-16 | Method for actvating natural killer cells by tumor cell preparation in vitro |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012224042A Division JP5906168B2 (ja) | 2005-03-17 | 2012-10-09 | 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法 |
| JP2014212302A Division JP2015012876A (ja) | 2005-03-17 | 2014-10-17 | 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008536487A JP2008536487A (ja) | 2008-09-11 |
| JP2008536487A5 true JP2008536487A5 (enExample) | 2009-03-12 |
| JP5663135B2 JP5663135B2 (ja) | 2015-02-04 |
Family
ID=36992099
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008501411A Expired - Fee Related JP5663135B2 (ja) | 2005-03-17 | 2006-03-16 | 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法 |
| JP2012224042A Active JP5906168B2 (ja) | 2005-03-17 | 2012-10-09 | 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法 |
| JP2014212302A Withdrawn JP2015012876A (ja) | 2005-03-17 | 2014-10-17 | 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012224042A Active JP5906168B2 (ja) | 2005-03-17 | 2012-10-09 | 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法 |
| JP2014212302A Withdrawn JP2015012876A (ja) | 2005-03-17 | 2014-10-17 | 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8257970B2 (enExample) |
| EP (2) | EP1863905B1 (enExample) |
| JP (3) | JP5663135B2 (enExample) |
| AU (1) | AU2006224313B2 (enExample) |
| CA (1) | CA2601197C (enExample) |
| DK (1) | DK1863905T3 (enExample) |
| ES (1) | ES2566335T3 (enExample) |
| PL (1) | PL1863905T3 (enExample) |
| WO (1) | WO2006097743A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007238660C1 (en) | 2006-04-14 | 2013-11-07 | Astellas Institute For Regenerative Medicine | Hemangio-colony forming cells |
| AU2009259699B2 (en) * | 2008-05-29 | 2014-01-23 | Transgene Sa | Biomarker for selecting patients and related methods |
| SG177595A1 (en) * | 2009-07-10 | 2012-03-29 | Mark Lowdell | Preserved compositions of activated nk cells and methods of using the same |
| US8961956B2 (en) | 2011-11-30 | 2015-02-24 | Ocata Therapeutics, Inc. | Mesenchymal stromal cells and uses related thereto |
| PL2785359T3 (pl) | 2011-11-30 | 2018-12-31 | Astellas Institute For Regenerative Medicine | Mezenchymalne komórki zrębowe i związane z nimi zastosowania |
| WO2013132256A1 (en) | 2012-03-07 | 2013-09-12 | Ucl Business Plc | Compositions and methods for treating viral-mediated infection and disease in immunocompromised individuals |
| WO2013168978A1 (ko) * | 2012-05-07 | 2013-11-14 | 고려대학교 산학협력단 | 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법 |
| KR101520534B1 (ko) | 2012-05-07 | 2015-05-21 | 고려대학교 산학협력단 | 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법 |
| WO2014011407A2 (en) | 2012-07-12 | 2014-01-16 | Imstem Biotechnology, Inc. | Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof |
| CA2896053A1 (en) | 2012-12-21 | 2014-06-26 | Ocata Therapeutics, Inc. | Methods for production of platelets from pluripotent stem cells and compositions thereof |
| WO2016033690A1 (en) * | 2014-09-04 | 2016-03-10 | Stemcell Technologies Inc. | Soluble antibody complexes for t cell or nk cell activation and expansion |
| US10758567B2 (en) | 2015-09-16 | 2020-09-01 | Immune Ventures LLC | In vivo priming of natural killer cells |
| JP6850297B2 (ja) * | 2015-12-07 | 2021-03-31 | イミューン ベンチャーズ, リミテッド ライアビリティ カンパニーImmune Ventures, Llc | ナチュラルキラー細胞の生体内プライミング |
| EP3596201A4 (en) * | 2017-03-15 | 2020-12-09 | Immune Ventures, LLC | IN VIVO PRIMING OF NATURAL KILLER CELLS |
| AU2019215034C1 (en) | 2018-02-01 | 2022-01-06 | Nkmax Co., Ltd. | Method of producing natural killer cells and composition for treating cancer |
| CA3109361A1 (en) * | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
| KR20210069639A (ko) | 2018-08-30 | 2021-06-11 | 에이치씨더블유 바이올로직스, 인크. | 단일-사슬 키메라 폴리펩타이드 및 이의 용도 |
| EP3844181B1 (en) | 2018-08-30 | 2025-11-12 | ImmunityBio, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| JP6838750B2 (ja) * | 2019-01-21 | 2021-03-03 | 株式会社ガイアバイオメディシン | Ｎｋ細胞を含む細胞集団の製造方法 |
| CN114269903B (zh) * | 2019-06-21 | 2025-11-25 | 免疫生物公司 | 多链嵌合多肽和其用途 |
| US12398189B2 (en) | 2020-02-11 | 2025-08-26 | HCW Biologics, Inc. | Methods of activating regulatory T cells |
| KR20220140535A (ko) | 2020-02-11 | 2022-10-18 | 에이치씨더블유 바이올로직스, 인크. | 크로마토그래피 수지 및 이의 용도 |
| IL295077A (en) | 2020-02-11 | 2022-09-01 | Hcw Biologics Inc | Methods of treating age-related and inflammatory diseases |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| KR20250118299A (ko) * | 2024-01-29 | 2025-08-06 | 인하대학교 산학협력단 | 전기자극 시스템을 활용한 자연살해세포의 암세포 살상 능력 증진 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2263205T3 (es) * | 1997-04-30 | 2006-12-01 | Hans Klingemann | Estirpes celulares citoliticas naturales y metodos de uso. |
| US6849452B1 (en) * | 1998-03-03 | 2005-02-01 | Institut Gustave Roussy | Methods for activating natural killer (NK) cells and means for carrying out said methods |
| JP5356648B2 (ja) | 2003-02-20 | 2013-12-04 | シアトル ジェネティックス， インコーポレイテッド | 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用 |
| US7435596B2 (en) * | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
-
2006
- 2006-03-16 AU AU2006224313A patent/AU2006224313B2/en not_active Ceased
- 2006-03-16 CA CA2601197A patent/CA2601197C/en not_active Expired - Fee Related
- 2006-03-16 EP EP06726410.1A patent/EP1863905B1/en not_active Not-in-force
- 2006-03-16 DK DK06726410.1T patent/DK1863905T3/en active
- 2006-03-16 PL PL06726410T patent/PL1863905T3/pl unknown
- 2006-03-16 JP JP2008501411A patent/JP5663135B2/ja not_active Expired - Fee Related
- 2006-03-16 WO PCT/GB2006/000960 patent/WO2006097743A2/en not_active Ceased
- 2006-03-16 ES ES06726410.1T patent/ES2566335T3/es active Active
- 2006-03-16 EP EP11002652.3A patent/EP2399594B1/en active Active
-
2007
- 2007-09-17 US US11/856,466 patent/US8257970B2/en not_active Expired - Fee Related
-
2012
- 2012-08-31 US US13/601,153 patent/US8637308B2/en not_active Expired - Fee Related
- 2012-10-09 JP JP2012224042A patent/JP5906168B2/ja active Active
-
2013
- 2013-11-21 US US14/086,768 patent/US9655925B2/en not_active Expired - Fee Related
-
2014
- 2014-10-17 JP JP2014212302A patent/JP2015012876A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008536487A5 (enExample) | ||
| Ginckels et al. | Oxidative stress and inflammation in cardiovascular diseases and cancer: role of non-coding RNAs | |
| Gkikas et al. | The role of mitophagy in innate immunity | |
| Ho et al. | Scaffold-mediated CRISPR-Cas9 delivery system for acute myeloid leukemia therapy | |
| Saleem et al. | p53 is necessary for the adaptive changes in cellular milieu subsequent to an acute bout of endurance exercise | |
| Pancione et al. | Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis | |
| Nehrbas et al. | Extracellular vesicles and chemotherapy resistance in the AML microenvironment | |
| NO20075245L (no) | Eliminasjon av heterogen eller blandet cellepopulasjon i tumorer | |
| EP3064220A3 (en) | Compositions and methods for the treatment of infections and tumors | |
| Wang et al. | Exercise training preserves ischemic preconditioning in aged rat hearts by restoring the myocardial polyamine pool | |
| JP2016501013A5 (enExample) | ||
| JP2009507918A5 (enExample) | ||
| JP2008519047A5 (enExample) | ||
| JP2009232853A5 (enExample) | ||
| JP2009545620A5 (enExample) | ||
| Kanat et al. | Shattering the castle walls: Anti-stromal therapy for pancreatic cancer | |
| Li et al. | ADAR1 attenuates allogeneic graft rejection by suppressing miR‐21 biogenesis in macrophages and promoting M2 polarization | |
| Guo et al. | Betaine effects on morphology, proliferation, and p53-induced apoptosis of hela cervical carcinoma cells in vitro | |
| Maleki et al. | Multiple interactions between melatonin and non‐coding RNAs in cancer biology | |
| Wang et al. | Bioinspired one cell culture isolates highly tumorigenic and metastatic cancer stem cells capable of multilineage differentiation | |
| JP2018522880A5 (enExample) | ||
| WO2017087947A3 (en) | Method of treatment of follicular lymphoma with a btk inhibitor | |
| Huart et al. | Could protons and carbon ions be the silver bullets against pancreatic cancer? | |
| Ziko et al. | Mechanical Stress Promotes Cisplatin‐Induced Hepatocellular Carcinoma Cell Death | |
| Kim et al. | A3 adenosine receptor antagonist, truncated Thio-Cl-IB-MECA, induces apoptosis in T24 human bladder cancer cells |